Wall Street Zen Downgrades National Research (NASDAQ:NRC) to Hold

Key Points

• Wall Street Zen downgraded National Research from “Buy” to “Hold,” while Weiss Ratings separately cut its rating to “Sell.” MarketBeat’s consensus rating is “Hold,” with a $26.00 price target.
• National Research reported quarterly EPS of $0.31, beating estimates by $0.46, and revenue of $35.39 million versus the $34.90 million consensus.
• The stock opened at $21.19, with a market capitalization of approximately $482 million and a P/E ratio of 84.76; institutional investors and hedge funds own 47.26% of outstanding shares.

National Research (NASDAQ:NRC - Get Free Report) was downgraded by analysts at Wall Street Zen from a "buy" rating to a "hold" rating in a report released on Saturday.

NRC has been the topic of a number of other reports. Weiss Ratings downgraded National Research from a "hold (c-)" rating to a "sell (d+)" rating in a research report on Thursday, August 6th. Citizens Jmp raised their price objective on National Research from $23.00 to $26.00 and gave the stock a "market outperform" rating in a research report on Wednesday, July 29th. One research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, National Research currently has a consensus rating of "Hold" and a consensus price target of $26.00.

National Research Stock Down 0.6%

Shares of National Research stock opened at $21.19 on Friday. The company has a quick ratio of 0.65, a current ratio of 0.65 and a debt-to-equity ratio of 13.13. The company has a market cap of $481.99 million, a P/E ratio of 84.76 and a beta of 0.34. The firm's 50 day moving average price is $20.63 and its 200-day moving average price is $18.24. National Research has a 52-week low of $11.01 and a 52-week high of $23.68.

National Research (NASDAQ:NRC - Get Free Report) last posted its earnings results on Tuesday, July 28th. The company reported $0.31 EPS for the quarter, beating analysts' consensus estimates of ($0.15) by $0.46. The company had revenue of $35.39 million during the quarter, compared to analysts' expectations of $34.90 million. National Research had a net margin of 4.18% and a return on equity of 164.26%.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the stock. Cubist Systematic Strategies LLC purchased a new position in shares of National Research in the first quarter worth $118,000. AQR Capital Management LLC grew its holdings in shares of National Research by 168.6% during the first quarter. AQR Capital Management LLC now owns 108,134 shares of the company's stock valued at $1,384,000 after buying an additional 67,882 shares during the last quarter. Jane Street Group LLC grew its holdings in shares of National Research by 394.2% during the first quarter. Jane Street Group LLC now owns 52,411 shares of the company's stock valued at $671,000 after buying an additional 41,806 shares during the last quarter. Strs Ohio acquired a new position in shares of National Research in the 1st quarter valued at $33,000. Finally, M&T Bank Corp increased its position in shares of National Research by 6.4% in the 2nd quarter. M&T Bank Corp now owns 13,608 shares of the company's stock valued at $229,000 after acquiring an additional 823 shares during the period. Institutional investors and hedge funds own 47.26% of the company's stock.

National Research Company Profile

National Research Corp NASDAQ: NRC, also known as NRC Health, is a healthcare analytics and performance improvement company specializing in patient and employee experience measurement. The company's cloud-based platform enables healthcare providers to collect real-time feedback through patient satisfaction surveys, post-discharge outreach, and employee engagement tools. NRC Health integrates clinical, operational and financial data to deliver actionable insights that support quality improvement initiatives and value-based care programs.

Since its founding in the early 1990s and headquartered in Lincoln, Nebraska, National Research has expanded beyond its regional roots to serve more than 1,600 hospitals and 12,000 care sites across the United States and Canada.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source